MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics - Takeaways - MDSpire

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • By

  • Rocío Maseda

  • María Carmen Arriba

  • Lucía Martínez-Santamaría

  • Eva Jiménez

  • Sara Herráiz-Gil

  • Nuria Illera

  • Lucía Quintana-Castanedo

  • Marta García

  • Susana Suárez-Sancho

  • Rosa Yáñez

  • Isabel Pérez-Conde

  • Marta Carretero

  • Magdalena Martínez-Queipo

  • Raquel de Paz

  • Carlos León

  • Víctor Jiménez-Yuste

  • Alberto M. Borobia

  • Ángeles Vicente

  • Su M. Lwin

  • John A. McGrath

  • María Eugenia Fernández-Santos

  • Nora Butta

  • Rosa Sacedón

  • Marcela del Río

  • Raúl de Lucas

  • María José Escámez

  • May 5, 2026

  • 0 min

Share

  • 1

    The MesenSistem-EB trial evaluated haploidentical BM-MSC therapy for recessive dystrophic epidermolysis bullosa (RDEB) in nine children.

  • 2

    MSC therapy was well-tolerated, with significant improvements in disease severity, pruritus, and inflammation observed in most patients.

  • 3

    Responses to MSC treatment correlated with changes in systemic inflammatory mediators MCP1 and sCD40L, suggesting their potential as predictive biomarkers.

  • 4

    Post-infusion immune cell changes included increased CLA expression on monocytes and partial recovery of memory CD8+ T cells.

  • 5

    The study supports BM-MSC as a safe anti-inflammatory intervention for RDEB, highlighting individual variability in therapeutic response.

Original Source(s)

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • by Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, Eva Jiménez, Sara Herráiz-Gil, Nuria Illera, Lucía Quintana-Castanedo, Marta García, Susana Suárez-Sancho, Rosa Yáñez, Isabel Pérez-Conde, Marta Carretero, Magdalena Martínez-Queipo, Raquel de Paz, Carlos León, Víctor Jiménez-Yuste, Alberto M. Borobia, Ángeles Vicente, Su M. Lwin, John A. McGrath, María Eugenia Fernández-Santos, Nora Butta, Rosa Sacedón, Marcela del Río, Raúl de Lucas, María José Escámez

  • May 5, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential